Lenka Besse

Cantonal Hospital St. Gallen
Sankt Gallen, SG, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Proteome profiling reveals NQO2 activity contributing to proteasome inhibitor resistance in multiple myeloma cell lines.

Proteome profiling reveals NQO2 activity contributing to proteasome inhibitor resistance in multiple myeloma cell lines.

Journal: Molecular & cellular proteomics : MCP

Published: May 13, 2026

Ceritinib overcomes proteasome inhibitor resistance in multiple myeloma by suppressing the protein folding response.

Ceritinib overcomes proteasome inhibitor resistance in multiple myeloma by suppressing the protein folding response.

Journal: Haematologica

Published: September 23, 2025

Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma.

Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma.

Journal: Clinical epigenetics

Published: July 03, 2025

Correction: Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.

Correction: Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.

Journal: Experimental hematology & oncology

Published: June 13, 2025

Open-label nonrandomized phase IB study to characterize the safety and recommended dose of tinostamustine in combination with nivolumab in patients with advanced melanoma (ENIgMA).

Open-label nonrandomized phase IB study to characterize the safety and recommended dose of tinostamustine in combination with nivolumab in patients with advanced melanoma (ENIgMA).

Journal: Melanoma research

Published: April 23, 2025

Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens.

Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens.

Journal: Blood

Published: November 08, 2024

Carfilzomib-specific proteasome β5/β2 inhibition drives cardiotoxicity via remodeling of protein homeostasis and the renin-angiotensin-system.

Carfilzomib-specific proteasome β5/β2 inhibition drives cardiotoxicity via remodeling of protein homeostasis and the renin-angiotensin-system.

Journal: iScience

Published: November 01, 2024

Targeting proteostasis in multiple myeloma through inhibition of LTK.

Targeting proteostasis in multiple myeloma through inhibition of LTK.

Journal: Leukemia

Published: September 08, 2024

HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.

HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.

Journal: British journal of cancer

Published: July 17, 2023

Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.

Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.

Journal: Experimental hematology & oncology

Published: May 30, 2023

A replicating LCMV-based vaccine for the treatment of solid tumors.

A replicating LCMV-based vaccine for the treatment of solid tumors.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: April 17, 2023

The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.

The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.

Journal: Scientific reports

Published: October 11, 2022

Showing 1-12 of 41

Last Updated: 09/26/2026